Takara Bio Inc.

Global Organoids Market to grow at a CAGR of ~14% by 2030, driven by personalized medicine, organoid use in drug discovery, and cancer research. North America leads the market, with key players including Thermofisher Scientific Inc., StemCell Technologies Inc., and others. Organoids mimic human organs, aiding in disease modeling and drug testing, but face challenges like high costs and limited vascularization.

The Cas nuclease market is forecasted to grow from $2.75 billion in 2023 to $6.56 billion by 2028 at a CAGR of 19.0%, driven by advancements in genome editing, increased biotechnology funding, and demand for personalized medicine.

The global induced pluripotent stem cells (iPSCs) market, valued at USD 1.88 billion in 2023, is projected to grow to USD 4.48 billion by 2032, driven by advancements in regenerative and personalized medicine, drug discovery, and increased investments in stem cell research. Key market participants focus on improving iPSC generation methods, while challenges include high production costs, ethical issues, and regulatory complexities. North America leads the market, with Asia-Pacific showing rapid growth.

The biotechnology reagents market is projected to grow from $86.17 billion in 2024 to $124.95 billion in 2028 at a CAGR of 9.7%, driven by factors like biopharmaceutical development, genomics research, and the rise of PCR technology.

Global exosome market to grow at ~20% CAGR by 2030, driven by chronic disease incidence, diagnostic improvements, and personalized medicine interest. North America leads, with key players like Danaher and Thermo Fisher Scientific. Notable developments include Aruna Bio's US patent for neural exosomes and EXO Biologics' EUR 16 million Series A funding.

The Immunohistochemistry Market is projected to grow from USD 3.1 billion in 2023 to USD 5.5 billion by 2031, at a CAGR of 7.4%. Factors driving growth include automation, advanced IHC solutions, and increased demand for personalized medicine. Multiplexed IHC, enabling detailed analysis from a single sample, is a key emerging technology. North America leads in market share due to biotech advancements and high cancer prevalence.

The mRNA synthesis & manufacturing market is projected to reach USD 738.3 million by 2029, driven by mRNA vaccine development and technology advancements. Consumables dominate the market, with pharmaceutical and biotechnology companies leading as end users. Asia Pacific is expected to grow fastest due to increased healthcare expenditure and investments in biopharmaceuticals.

DelveInsight's Exosomes Pipeline Insight 2024 report details 75+ therapies from 70+ companies, including Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, and others. Key therapies like ExoCoVac, COYA 201, EV-101, and StemXO are in various clinical trial phases. Notable approvals include Aruna Bio's AB126 for acute ischemic stroke and EXO Biologics' EXOB-001 for bronchopulmonary dysplasia. The report covers mechanism of action, route of administration, and market dynamics.

The Asia-Pacific DNA methylation detection technology market, valued at $443.6 million in 2023, is projected to reach $2.28 billion by 2033, driven by rising startups, academic collaborations, and the use of DNA methylation as epigenetic biomarkers. Technological advancements like NGS and high-throughput platforms are enhancing precision and affordability, crucial for personalized medicine and better patient outcomes.